Treatment options for metastatic hormone-sensitive prostate cancer

The treatment landscape for metastatic, hormone-sensitive prostate cancer has transformed in recent years, with the emphasis now on early treatment intensification through a combination approach to systemic therapy. Now that the addition of a second-generation anti-androgen or docetaxel is known to confer a survival benefit, androgen deprivation therapy (ADT) monotherapy is no longer considered sufficient. In fact, for selected patients with de novo, high-volume, metastatic, hormone-sensitive prostate cancer, triplet therapy with ADT, an androgen-receptor inhibitor, and docetaxel is most efficacious.